Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil - PubMed (original) (raw)

. 2006 Oct;55(10):1488-95.

doi: 10.1136/gut.2005.077099. Epub 2006 Feb 4.

W Yoo, S P Hong, Y J Chang, S K Yu, J H Kim, Y S Seo, H J Chung, M S Moon, S-O Kim, K S Byun, C H Lee

Affiliations

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil

J E Yeon et al. Gut. 2006 Oct.

Abstract

Background: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV). The cumulative incidence of ADV resistant mutations in the nucleoside/-tide treatment naive chronic hepatitis B patient (CHB) at weeks 48, 96, and 144 was 0, 0.8-3%, and approximately 5.9%, respectively.

Aims: The aim of this study was to characterise the genotypic and phenotypic mutation profiles to ADV in 67 LMV resistant CHB patients who were treated with ADV.

Methods: Serum HBV DNA was quantified by real time polymerase chain reaction. The ADV mutant was detected using matrix assisted laser desorption/ionisation time of flight mass spectrometry based genotyping assays, termed restriction fragment mass polymorphism (RFMP).

Results: RFMP analysis revealed that a total of 11 amino acid substitutions developed in the rt domain of the HBV polymerase in nine patients. The cumulative incidence of genotypic ADV resistance at months 12 and 24 was 6.4% and 25.4%, respectively. The rtA181V, rtN236T, and rtA181T mutations were detected in five, four, and two of the 67 patients at treatment months 12-17, 3-19, and 7-20, respectively. Serial quantification of serum HBV DNA revealed that two patients with the rtA181V mutation, with or without the rtN236T mutation, and one patient with the rtA181T mutation displayed HBV DNA rebound.

Conclusion: Emergence of the ADV mutation in LMV resistant patients who are treated with ADV appeared to present earlier and more frequently than was reported in previous studies on nucleoside/-tide treatment naive patients.

PubMed Disclaimer

Figures

Comment in

References

    1. Lai C L, Dienstag J, Schiff E.et al Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 200336687–696. - PubMed
    1. Chayama K, Suzuki Y, Kobayashi M.et al Emergence and take over of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and retake over by wild type after cessation of therapy. Hepatology 1998271711–1716. - PubMed
    1. Westland C E, Yang H, Delaney W Et.et al Activity of adefovir dipivoxil against all patterns of lamivudine‐resistant hepatitis B viruses in patients. J Viral Hepat 20051267–73. - PubMed
    1. Perrillo R, Hann H W, Mutimer D.et al Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 200412681–90. - PubMed
    1. Marcellin P, Chang T T, Lim S G.et al Adefovir dipivoxil for the treatment of hepatitis B e antigen‐positive chronic hepatitis B. N Engl J Med 2003348808–816. - PubMed

MeSH terms

Substances

LinkOut - more resources